• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Oncology >Agranulocytosis Associated With Spironolactone Therapy: A Case Report
【24h】

Agranulocytosis Associated With Spironolactone Therapy: A Case Report

机译：螺内酯治疗相关的粒细胞缺乏症：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Herein, we report a case where agranulocytosis occurred after spironolactone administration. Patient presented with non-descript constitutional symptoms suggestive of a viral etiology associated to new onset agranulocytosis with neutrophilic maturation arrest on bone marrow biopsy. Patient's medical history included chronic liver disease as well as new onset acute renal insufficiency. Upon review of patient's medications, initiation of spironolactone was noted 4 weeks prior to admission. Few cases of agranulocytosis secondary to spironolactone have been reported in the literature, most of which were also in association with both renal insufficiency and chronic liver disease. Discontinuation of spironolactone resulted in normalization of granulocyte count within 3 weeks. As patients with chronic liver disease are frequently given spironolactone, we recommend monitoring blood counts 4 - 8 weeks following initiation of therapy to detect and treat this potentially life threatening complication.doi:10.4021/wjon356w
机译：在本文中，我们报道了螺内酯给药后发生粒细胞缺乏症的情况。患者出现非描述性的体质症状，提示病毒病因与骨髓活检中新发粒细胞缺乏伴嗜中性粒细胞成熟停滞有关。患者的病史包括慢性肝病以及新发的急性肾功能不全。复查患者的药物后，在入院前4周记录了螺内酯的开始。文献报道很少有螺内酯继发性粒细胞缺乏症的病例，其中大多数也与肾功能不全和慢性肝病有关。螺内酯的中止导致粒细胞计数在3周内恢复正常。由于慢性肝病患者经常服用螺内酯，因此我们建议在开始治疗后4-8周监测血细胞计数，以检测和治疗这种可能危及生命的并发症。doi：10.4021 / wjon356w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号